| Bioactivity | PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3 nM and 60.8 nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research[1]. |
| Invitro | PLK1/BRD4-IN-5 (Compound SC10) 对三种肿瘤细胞系都具有显著的抗增殖活性 (MDA-MB-231 IC50 = 17.3 nM, MDA-MB-361 IC50 = 8.4 nM, MV4-11 IC50 = 5.4 nM)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PLK1/BRD4-IN-5 相关抗体: Apoptosis Analysis[1] Cell Line: |
| In Vivo | PLK1/BRD4-IN-5 在 Sprague-Dawley 大鼠体内的药动学参数[1]Route |
| Formula | C31H44N8O3 |
| Molar Mass | 576.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu J, et al. Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer. Bioorg Med Chem. 2024;101:117 |